9,339
Total Claims
$1.9M
Drug Cost
1,296
Beneficiaries
$1,458
Cost/Patient
Peer Comparison vs. 4,479 Interventional Cardiology providers
+38%
Cost per patient vs peers
$1,458 vs $1,054 avg
Brand vs Generic
100% generic
Brand: 0 claims · $0
Generic: 8,004 claims · $263K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Apixaban | 408 | $525K |
| Sacubitril/Valsartan | 180 | $295K |
| Rivaroxaban | 231 | $291K |
| Empagliflozin | 118 | $169K |
| Empagliflozin/Metformin Hcl | 62 | $86K |
| Evolocumab | 71 | $75K |
| Alirocumab | 40 | $52K |
| Dronedarone Hcl | 20 | $34K |
| Icosapent Ethyl | 62 | $28K |
| Rosuvastatin Calcium | 1,164 | $28K |
| Icosapent Ethyl | 26 | $27K |
| Pitavastatin Calcium | 22 | $21K |
| Ranolazine | 84 | $18K |
| Metoprolol Succinate | 563 | $13K |
| Diltiazem Hcl | 292 | $12K |
Prescribing Profile
71
Unique Drugs
$1.3M
Patient Profile
77
Avg Age
48%
Female
1.60
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations.Methodology · About